Data published in The Journal of Bone and Joint Surgery demonstrates that use of ChloraPrep is more effective than both DuraPrep and povidone-iodine, at eliminating overall bacteria from
Cardium Therapeutics has revealed that all patients enrolled in the MATRIX clinical study have completed their initial 12-week evaluation period. The company plans to provide detailed safety and
ISTA Pharmaceuticals (ISTA) has reported positive preliminary phase 3 results from the company’s Xibrom (bromfenac ophthalmic solution) 0.09% QD (once-daily) confirmatory clinical study. Xibrom 0.09% QD achieved statistical
AstraZeneca, a manufacturer of prescription pharmaceuticals, biologics and vaccines, has opened its new office in Azerbaijan to expand its market presence – reported Fineko/abc.az. According to the news
Karo Bio has reported that in the beginning of September 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the
Graymark has acquired somniCare and somniTech (collectively, Somni) from Avastra. The Somni companies provide personalized sleep disorder testing and treatment as well as comprehensive care in sleep apnea
An EUA authorizes the use of unapproved medical products or unapproved uses of approved medical products during a declared public health emergency. “The FDA worked quickly with the
Seattle Genetics has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. The company has said that Brentuximab vedotin is
CSL Biotherapies has announced the initiation of the company’s first US clinical trials of its candidate Influenza A/H1N1 2009 vaccine. The studies are expected to determine the safety
Osteologix, a Virginia-based biopharmaceutical company working in the area of musculoskeletal diseases, such as osteoporosis, has announced that the Japan Patent Office (JPO) has issued a Decision to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.